The FDA said it has set April 28 as the date of an advisory committee meeting on Cambridge, MA-based Vertex Pharmaceuticals’ (NASADAQ:[[ticker:VRTX]]) application for approval of its experimental hepatitis C drug telaprevir. The agency has a track record of often, but not always, following the recommendations of such advisory groups. Vertex is seeking approval of its drug for use in treating chronic hepatitis C genotype 1 infection in combination with two approved medicines for the disease in adult patients with “compensated liver disease who are previously untreated or who have failed previous therapy,” according to the FDA. Vertex has said that the likely date of the agency’s decision on the company’s application for approval of telaprevir is May 23.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
